Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease
- PMID: 11878916
- DOI: 10.1006/viro.2001.1184
Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease
Abstract
Human immunodeficiency virus type 1 (HIV-1) protease activity is targeted at nine cleavage sites comprising different amino acid sequences in the viral Gag-Pol polyprotein. Amino acid polymorphisms in protease and in regions of Gag, particularly p7(NC) and the C-cleavage site between p2 and p7(NC), occur in natural variants of HIV-1 within infected patients. Studies were designed to examine the role of natural polymorphisms in protease and to identify determinants in Gag that modulate protease processing activity. Closely related Gag-Pol regions from an HIV-1-infected mother and two children were evaluated for processing in an inducible expression system, for protease activity on cleavage-site analogues, and for impact on replication by recombinant viruses. Gag-Pol regions displayed one of three processing phenotypes based on the appearance of Gag intermediates and accumulation of mature p24(CA). Gag-Pol regions that were processed rapidly to produce p24(CA) resulted in high-level replication by recombinant viruses, while slow-processing Gag-Pol variants resulted in recombinant viruses that replicated with reduced kinetics in both T cell lines and peripheral blood mononuclear cells. Direct impact by Gag sequences on processing by protease was assessed by construction of chimeric Gag-Pol regions and by site-directed mutagenesis. Optimal protease activity occurred when Gag and Pol regions were derived from the same gag-pol allele. Heterologous Gag regions generally diminished rates and extent of protease processing. Natural polymorphisms in novel positions in p7(NC) and the C-cleavage site have a dominant effect on protease processing activity. Accumulation of Gag products after processing at the C site appears to delay subsequent cleavage and production of mature p24(CA).
Similar articles
-
Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.Virology. 1996 May 15;219(2):407-16. doi: 10.1006/viro.1996.0266. Virology. 1996. PMID: 8638406
-
Contribution of the Gag-Pol transframe domain p6* and its coding sequence to morphogenesis and replication of human immunodeficiency virus type 1.Virology. 2004 Dec 5;330(1):271-83. doi: 10.1016/j.virol.2004.09.013. Virology. 2004. PMID: 15527852
-
Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles.Virology. 1993 Apr;193(2):661-71. doi: 10.1006/viro.1993.1174. Virology. 1993. PMID: 7681610
-
HIV-1 gag proteins: diverse functions in the virus life cycle.Virology. 1998 Nov 10;251(1):1-15. doi: 10.1006/viro.1998.9398. Virology. 1998. PMID: 9813197 Review.
-
Controlling elements in replication of the human immunodeficiency virus type 1.Cell Mol Biol (Noisy-le-grand). 1997 May;43(3):443-54. Cell Mol Biol (Noisy-le-grand). 1997. PMID: 9193800 Review.
Cited by
-
Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor.AIDS. 2009 Aug 24;23(13):1631-40. doi: 10.1097/QAD.0b013e32832e0599. AIDS. 2009. PMID: 19625947 Free PMC article.
-
Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.Virology. 2008 Sep 1;378(2):272-81. doi: 10.1016/j.virol.2008.05.029. Epub 2008 Jul 2. Virology. 2008. PMID: 18599104 Free PMC article.
-
Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children.Immunol Res. 2008;40(3):271-86. doi: 10.1007/s12026-007-0031-1. Immunol Res. 2008. PMID: 17952387
-
Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.Biochemistry. 2006 May 2;45(17):5468-77. doi: 10.1021/bi051886s. Biochemistry. 2006. PMID: 16634628 Free PMC article.
-
New findings in cleavage sites variability across groups, subtypes and recombinants of human immunodeficiency virus type 1.PLoS One. 2014 Feb 7;9(2):e88099. doi: 10.1371/journal.pone.0088099. eCollection 2014. PLoS One. 2014. PMID: 24516589 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources